NVOS — Novo Integrated Sciences Balance Sheet
0.000.00%
- $12.67m
- $15.01m
- $12.57m
- 30
- 69
- 14
- 31
Annual balance sheet for Novo Integrated Sciences, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 2.08 | 2.07 | 8.29 | 2.18 | 0.416 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.76 | 2.04 | 2.28 | 2.1 | 2.52 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 4.1 | 4.29 | 11.1 | 5.73 | 4.39 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.41 | 3.16 | 8.61 | 8.47 | 7.37 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 32.3 | 35.4 | 62 | 40.9 | 35.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.03 | 2.6 | 8.46 | 14.1 | 7.9 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.69 | 5.77 | 18.1 | 18.6 | 10.7 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 25.6 | 29.6 | 43.9 | 22.3 | 24.8 |
Total Liabilities & Shareholders' Equity | 32.3 | 35.4 | 62 | 40.9 | 35.6 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |